Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease

Siddharth Arora; Naomi P. Visanji; Tiago A. Mestre; Athanasios Tsanas; Amaal AlDakheel; Barbara S. Connolly; Carmen Gasca-Salas; Drew S. Kern; Jennifer Jain; Elizabeth J. Slow; Achinoam Faust-Socher; Anthony E. Lang; Max A. Little; Connie Marras

doi:10.3233/JPD-181389

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease

Siddharth Arora, Naomi P. Visanji, Tiago A. Mestre, Athanasios Tsanas, Amaal AlDakheel, Barbara S. Connolly, Carmen Gasca-Salas, Drew S. Kern, Jennifer Jain, Elizabeth J. Slow, Achinoam Faust-Socher, Anthony E. Lang, Max A. Little, Connie Marras

Research output: Contribution to journal › Article › peer-review

Abstract

We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.

Original language	English
Pages (from-to)	503-510
Number of pages	8
Journal	Journal of Parkinson's Disease
Volume	8
Issue number	4
DOIs	https://doi.org/10.3233/JPD-181389
Publication status	Published - 17 Oct 2018

Bibliographical note

Keywords

biomarker
LRRK2 mutation
Parkinson’s disease
voice

Access to Document

10.3233/JPD-181389

Investigating Voice as a Biomarker for leucine-rich repeat kinase 2-Associated Parkinson’s Disease
©2018 IOS Press.
Accepted author manuscript, 1.08 MB

Cite this

Arora, S., Visanji, N. P., Mestre, T. A., Tsanas, A., AlDakheel, A., Connolly, B. S., Gasca-Salas, C., Kern, D. S., Jain, J., Slow, E. J., Faust-Socher, A., Lang, A. E., Little, M. A., & Marras, C. (2018). Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. Journal of Parkinson's Disease, 8(4), 503-510. https://doi.org/10.3233/JPD-181389

@article{ae1dd8d9b5e545098d474cd9316859b1,

title = "Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease",

abstract = "We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.",

keywords = "biomarker, LRRK2 mutation, Parkinson{\textquoteright}s disease, voice",

author = "Siddharth Arora and Visanji, {Naomi P.} and Mestre, {Tiago A.} and Athanasios Tsanas and Amaal AlDakheel and Connolly, {Barbara S.} and Carmen Gasca-Salas and Kern, {Drew S.} and Jennifer Jain and Slow, {Elizabeth J.} and Achinoam Faust-Socher and Lang, {Anthony E.} and Little, {Max A.} and Connie Marras",

note = "{\textcopyright}2018 IOS Press. ",

year = "2018",

month = oct,

day = "17",

doi = "10.3233/JPD-181389",

language = "English",

volume = "8",

pages = "503--510",

journal = "Journal of Parkinson's Disease",

issn = "1877-7171",

publisher = "IOS",

number = "4",

}

Arora, S, Visanji, NP, Mestre, TA, Tsanas, A, AlDakheel, A, Connolly, BS, Gasca-Salas, C, Kern, DS, Jain, J, Slow, EJ, Faust-Socher, A, Lang, AE, Little, MA & Marras, C 2018, 'Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease', Journal of Parkinson's Disease, vol. 8, no. 4, pp. 503-510. https://doi.org/10.3233/JPD-181389

TY - JOUR

T1 - Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease

AU - Arora, Siddharth

AU - Visanji, Naomi P.

AU - Mestre, Tiago A.

AU - Tsanas, Athanasios

AU - AlDakheel, Amaal

AU - Connolly, Barbara S.

AU - Gasca-Salas, Carmen

AU - Kern, Drew S.

AU - Jain, Jennifer

AU - Slow, Elizabeth J.

AU - Faust-Socher, Achinoam

AU - Lang, Anthony E.

AU - Little, Max A.

AU - Marras, Connie

PY - 2018/10/17

Y1 - 2018/10/17

N2 - We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.

AB - We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.

KW - biomarker

KW - LRRK2 mutation

KW - Parkinson’s disease

KW - voice

UR - http://www.scopus.com/inward/record.url?scp=85055144464&partnerID=8YFLogxK

UR - https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181389

U2 - 10.3233/JPD-181389

DO - 10.3233/JPD-181389

M3 - Article

C2 - 30248062

AN - SCOPUS:85055144464

SN - 1877-7171

VL - 8

SP - 503

EP - 510

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 4

ER -

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this